HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8

Benzinga Newsdesk www.benzinga.com Positive 73.9%

Neg 0% Neu 0% Pos 73.9%

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $5 to $8.